- Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami - GAITHERSBURG, Md., May 10, 2022 – [...]
Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank [...]
Gaithersburg, Md., Dec. 14, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced [...]
Former CMO Metin Kurtoglu, M.D., Ph.D., appointed as the Company’s first Chief Operating Officer Cartesian expands cGMP manufacturing facility to support growing clinical pipeline [...]
In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification [...]
Award increases NIH funding to $6.3 million to date from three independent NIH Institutes.Gaithersburg, MD, May 4, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical [...]
Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without requiring lymphodepleting chemotherapy Cartesian plans to enroll up to [...]
Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS. [...]
First CAR-T to enter clinical development for an autoimmune disease Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential [...]